Symbols / ATXI $0.35 +0.00% Avenue Therapeutics, Inc.

Healthcare • Biotechnology • United States • PNK
ATXI Chart
About

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 1.11M
Enterprise Value -1.70M Income -2.91M Sales 1.40M
Book/sh 0.57 Cash/sh 0.87 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E 0.29 Forward P/E -0.11 PEG —
P/S 0.79 P/B 0.61 P/C —
EV/EBITDA — EV/Sales -1.21 Quick Ratio 2.60
Current Ratio 2.67 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.93 EPS next Y -3.14 EPS Growth —
Revenue Growth — Earnings 2024-11-14 16:00 ROA -73.31%
ROE -159.82% ROIC — Gross Margin 100.00%
Oper. Margin -234.05% Profit Margin -207.19% Shs Outstand 3.18M
Shs Float 2.85M Short Float 2.83% Short Ratio 0.65
Short Interest — 52W High 0.97 52W Low 0.15
Beta — Avg Volume 6.11K Volume 40.00
Target Price — Recom None Prev Close $0.35
Price $0.35 Change 0.00%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.35
Latest analyst target
3. DCF / Fair value
$-10.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.35
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-12-11 init Maxim Group — → Buy $1
2023-04-03 init Aegis Capital — → Buy $32
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-02 FORTRESS BIOTECH, INC. Beneficial Owner of more than 10% of a Class of Security — 111,209 $0.00 $0
2025-03-31 FORTRESS BIOTECH, INC. Beneficial Owner of more than 10% of a Class of Security — 33,724 $0.00 $0
2024-12-02 HERSKOWITZ NEIL Director — 23 $2.00 $46
2024-11-05 KRANZLER JAY D Director — 61 $2.24 $137
2024-09-30 KRANZLER JAY D Director — 500 $2.40 $1,250
2024-09-23 MACLEAN ALEXANDRA M.D. Chief Executive Officer — 170,000 $0.00 $0
2024-09-23 JIN DAVID Chief Operating Officer — 65,000 $0.00 $0
2024-04-16 FORTRESS BIOTECH, INC. Beneficial Owner of more than 10% of a Class of Security — 413,507 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.40
0.00
0.00
0.00
Operating Revenue
1.40
0.00
0.00
0.00
Operating Expense
4.69
-58.43%
11.28
-22.40%
14.54
+80.78%
8.04
Research And Development
1.04
-84.39%
6.64
-35.87%
10.36
+284.03%
2.70
Selling General And Administration
3.65
-21.24%
4.64
+10.98%
4.18
-21.81%
5.34
General And Administrative Expense
3.65
-21.24%
4.64
+10.98%
4.18
-21.81%
5.34
Other Gand A
3.65
-21.24%
4.64
+10.98%
4.18
-21.81%
5.34
Total Expenses
4.69
-58.43%
11.28
-22.40%
14.54
+80.78%
8.04
Operating Income
-3.29
+70.88%
-11.28
+22.40%
-14.54
-80.78%
-8.04
Total Operating Income As Reported
-3.08
+72.68%
-11.28
+22.40%
-14.54
-80.78%
-8.04
EBITDA
-3.29
+70.88%
-11.28
-11.10%
-10.16
-315.72%
-2.44
Normalized EBITDA
-3.50
+67.23%
-10.69
+25.81%
-14.41
-79.66%
-8.02
EBIT
-3.29
+70.88%
-11.28
-11.10%
-10.16
-315.72%
-2.44
Total Unusual Items
0.22
+137.01%
-0.59
-113.83%
4.26
-23.69%
5.58
Total Unusual Items Excluding Goodwill
0.22
+137.01%
-0.59
-113.83%
4.26
-23.69%
5.58
Special Income Charges
0.20
0.00
—
—
Net Income
-2.91
+75.03%
-11.65
-12.29%
-10.38
-192.15%
-3.55
Pretax Income
-2.95
+74.80%
-11.70
-11.52%
-10.49
-191.09%
-3.60
Net Non Operating Interest Income Expense
0.12
-31.25%
0.18
+185.44%
-0.21
+81.93%
-1.14
Interest Expense Non Operating
—
0.00
-100.00%
0.33
-71.38%
1.16
Net Interest Income
0.12
-31.25%
0.18
+185.44%
-0.21
+81.93%
-1.14
Interest Expense
—
0.00
-100.00%
0.33
-71.38%
1.16
Interest Income Non Operating
0.12
-31.25%
0.18
+39.68%
0.13
+530.00%
0.02
Interest Income
0.12
-31.25%
0.18
+39.68%
0.13
+530.00%
0.02
Other Income Expense
0.22
+137.01%
-0.59
-113.83%
4.26
-23.69%
5.58
Gain On Sale Of Security
0.01
+102.55%
-0.59
-113.83%
4.26
-23.69%
5.58
Gain On Sale Of Business
0.20
0.00
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-2.95
+74.80%
-11.70
-11.52%
-10.49
-191.09%
-3.60
Net Income From Continuing Operation Net Minority Interest
-2.91
+75.03%
-11.65
-12.29%
-10.38
-192.15%
-3.55
Net Income From Continuing And Discontinued Operation
-2.91
+75.03%
-11.65
-12.29%
-10.38
-192.15%
-3.55
Net Income Continuous Operations
-2.95
+74.80%
-11.70
-11.52%
-10.49
-191.09%
-3.60
Minority Interests
0.04
-13.64%
0.04
-60.36%
0.11
+117.65%
0.05
Normalized Income
-3.13
+71.73%
-11.06
+24.41%
-14.63
-60.26%
-9.13
Net Income Common Stockholders
-2.91
+75.03%
-11.65
-12.29%
-10.38
-192.15%
-3.55
Diluted EPS
-0.93
+94.11%
-15.79
+78.51%
-73.48
+39.89%
-122.25
Basic EPS
-0.93
+94.11%
-15.79
+78.51%
-73.48
+39.89%
-122.25
Basic Average Shares
3.13
+141.75%
1.30
+817.14%
0.14
+384.72%
0.03
Diluted Average Shares
3.13
+141.75%
1.30
+817.14%
0.14
+384.72%
0.03
Diluted NI Availto Com Stockholders
-2.91
+75.03%
-11.65
-12.29%
-10.38
-192.15%
-3.55
Line Item Trend 2023-12-31
Total Assets
1.85
Current Assets
1.85
Cash Cash Equivalents And Short Term Investments
1.78
Cash And Cash Equivalents
1.78
Receivables
—
Prepaid Assets
—
Other Current Assets
0.07
Total Non Current Assets
0.00
Total Liabilities Net Minority Interest
1.20
Current Liabilities
1.20
Payables And Accrued Expenses
0.60
Payables
0.40
Accounts Payable
0.08
Current Accrued Expenses
0.20
Pensionand Other Post Retirement Benefit Plans Current
0.01
Other Current Liabilities
0.59
Total Non Current Liabilities Net Minority Interest
0.00
Stockholders Equity
1.58
Common Stock Equity
1.58
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.34
Ordinary Shares Number
0.34
Treasury Shares Number
0.00
Additional Paid In Capital
92.51
Retained Earnings
-90.93
Minority Interest
-0.93
Total Equity Gross Minority Interest
0.65
Total Capitalization
1.58
Working Capital
0.65
Invested Capital
1.58
Net Tangible Assets
1.58
Tangible Book Value
1.58
Duefrom Related Parties Current
—
Dueto Related Parties Current
0.32
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-1.83
+79.69%
-9.03
+4.50%
-9.45
-24.42%
-7.60
Cash Flow From Continuing Operating Activities
-1.83
+79.69%
-9.03
+4.50%
-9.45
-24.42%
-7.60
Net Income From Continuing Operations
-2.95
+74.80%
-11.70
-11.52%
-10.49
-191.09%
-3.60
Other Non Cash Items
0.17
-74.77%
0.67
-85.77%
4.68
+782.83%
0.53
Stock Based Compensation
0.67
-46.20%
1.24
+36.42%
0.91
+39.60%
0.65
Operating Gains Losses
-0.02
-103.23%
0.59
+113.83%
-4.26
+23.69%
-5.58
Gain Loss On Investment Securities
-0.02
-103.23%
0.59
+113.83%
-4.26
+23.69%
-5.58
Change In Working Capital
0.30
+67.60%
0.18
+161.72%
-0.29
-171.08%
0.41
Change In Receivables
—
—
0.00
-100.00%
0.09
Change In Prepaid Assets
0.00
+118.18%
-0.01
-115.71%
0.07
+333.33%
-0.03
Change In Payables And Accrued Expense
0.30
+56.84%
0.19
+152.78%
-0.36
-203.45%
0.35
Investing Cash Flow
—
0.00
+100.00%
-3.00
0.00
Cash Flow From Continuing Investing Activities
—
0.00
+100.00%
-3.00
0.00
Capital Expenditure
—
—
-3.00
—
Net Intangibles Purchase And Sale
—
0.00
+100.00%
-3.00
0.00
Purchase Of Intangibles
—
0.00
+100.00%
-3.00
0.00
Financing Cash Flow
2.09
-78.71%
9.84
+30.71%
7.53
-28.60%
10.54
Cash Flow From Continuing Financing Activities
2.09
-78.71%
9.84
+30.71%
7.53
-28.60%
10.54
Net Common Stock Issuance
2.09
+29.02%
1.62
-78.43%
7.53
-27.60%
10.39
Common Stock Payments
—
—
0.00
+100.00%
-1.10
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-1.10
Proceeds From Stock Option Exercised
0.00
-100.00%
9.42
+942000.00%
0.00
-99.32%
0.15
Net Other Financing Charges
—
-1.21
—
-0.51
Changes In Cash
0.26
-67.82%
0.81
+116.47%
-4.92
-267.23%
2.94
Beginning Cash Position
2.59
+45.49%
1.78
-73.42%
6.71
+78.26%
3.76
End Cash Position
2.85
+10.06%
2.59
+45.49%
1.78
-73.42%
6.71
Free Cash Flow
-1.83
+79.69%
-9.03
+27.51%
-12.45
-63.92%
-7.60
Common Stock Issuance
2.09
+29.02%
1.62
-78.43%
7.53
-34.55%
11.50
Issuance Of Capital Stock
2.09
+29.02%
1.62
-78.43%
7.53
-34.55%
11.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category